ArticleTranslational lung cancer research2025

Navigating treatment sequencing in ALK-positive non-small cell lung cancer: lorlatinib as a key to prolonged survival?

Maiken Parm Ulhøi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.